Tackling post-traumatic stress disorder (PTSD) with methylone
Find out about developments in the world of PTSD research in our latest blog, where our clinical director Dr Iain Jordan provides a comprehensive overview. Delve into discussions on traditional treatments, the potential of methylone, and gain insights into our ongoing PTSD trial.
In recent years, significant strides have been made in the medical field regarding treatments for post-traumatic stress disorder (PTSD), notably in the use of MDMA (commonly known as ecstasy) to aid therapy. For individuals whose lives have been profoundly impacted by PTSD, these advancements offer additional options, especially when traditional treatments like psychotherapy and medication are not enough.
1: Existing Treatments for PTSD:
PTSD exacts a heavy toll, affecting mental, emotional, and physical well-being, as well as straining relationships and overall quality of life. Traditional treatments such as psychotherapy and medication have helped many individuals, but there remains a substantial portion of the population for whom these approaches do not work. This has left both patients and healthcare providers searching for new solutions. Research into new treatments will provide alternative options for those for whom existing treatments are ineffective.
2: Emerging Research in PTSD Treatment:
There is much excitement and hope in the field following highly promising results from recent pivotal studies of MDMA in the treatment of PTSD. MDMA produces effects such as increased feelings of wellbeing and connectedness to others, and decreased feelings of fear. These effects make it and similar medications highly promising for use alongside therapy for PTSD as they address many of the things that can make therapy challenging – including helping patients confront and process traumatic memories, improving their emotional well-being, and rebuilding their lives – all in a safe and trusting therapeutic relationship. MDMA is now on track to be approved by the FDA in the coming months, with the UK likely not far behind, though it is likely to be some time before it becomes widely available to the public.
3: Methylone PTSD Clinical Trial in the UK:
Methylone is a non-hallucinogenic, rapid-acting neuroplastogen with similar subjective effects to those described above and early research from Yale suggests rapid and enduring improvements in PTSD symptoms. Clerkenwell Health is proud to be running a trial of methylone for PTSD in London on behalf of Transcend Therapeutics. At Clerkenwell Health, our mission is to deliver rigorous research on a variety of novel treatments for mental health conditions. Our experienced research and clinical team prioritise patient wellbeing and safety at every stage of the process. When you join our trials, you become a crucial part of the cutting edge of psychiatric research worldwide.
Find out more: Join our PTSD Clinical Trial Today:
If you are keen on learning more about our PTSD clinical trials and wish to enrol in the methylone trial or any of our other clinical studies, click the sign up link below.
Interested in our PTSD clinical trial?
Interested in being a therapist on a PTSD psychedelics trial? Click here to view our psychedelic practitioner training programmes.